

Eisai strengthens R&D function for injectable drug formulations in Japan

06 October 2022 | News

Completes construction of its new injection/research building at Kawashima Industrial Park

Eisai has announced that as a part of the strategic investment towards the realization of its medium-term business plan “EWAY Future & Beyond”, it has completed construction of the new injection/research building “Eisai Medicine Innovation Technology Solutions” (EMITS) at the Kawashima Industrial Park located in Gifu Prefecture, Japan.

EMITS will be Eisai’s global base for formulation and modality research. In recent years, Eisai’s drug discovery targets have expanded to include modalities such as antibodies, antibody drug conjugates (ADCs), and nucleic acid drugs, in addition to conventional small molecule compounds.

At EMITS, Eisai will strengthen its injectable drug formulation development research function and drug delivery system (DDS) development function, including liposomal and lipid nanoparticle formulations, and address the development of various modalities.

Eisai aims to elevate the quality of the technology and knowledge of its formulation research function, and to become a base for disseminating innovation, technology, and solutions relating to formulations. The aggregate investment in the construction of EMITS is approximately 10 billion Japanese yen.

The Kawashima Industrial Park is Eisai’s global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing.